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Background: Varicella zoster virus (VZV) is a neurotropic alphaherpesvirus that infects humans and results in
chickenpox and herpes zoster. A number of VZV genes remain functionally uncharacterized and since VZV is an
obligate human pathogen, rigorous evaluation of VZV mutants in vivo remains challenging. Simian varicella virus
(SVV) is homologous to VZV and SVV infection of rhesus macaques (RM) closely mimics VZV infection of humans.
Recently the SVV genome was cloned as a bacterial artificial chromosome (BAC) and BAC-derived SVV displayed
similar replication kinetics as wild-type (WT) SVV in vitro.
Methods: RMs were infected with BAC-derived SVV or WT SVV at 4x105 PFU intrabronchially (N=8, 4 per group, sex
and age matched). We collected whole blood (PBMC) and bronchoalveolar lavage (BAL) at various days post-
infection (dpi) and sensory ganglia during latent infection (>84 dpi) at necropsy and compared disease progression,
viral replication, immune response and the establishment of latency.
Results: Viral replication kinetics and magnitude in bronchoalveolar lavage cells and whole blood as well as rash
severity and duration were similar in RMs infected with SVV BAC or WT SVV. Moreover, SVV-specific B and T cell
responses were comparable between BAC and WT-infected animals. Lastly, we measured viral DNA in sensory
ganglia from both cohorts of infected RMs during latent infection.
Conclusions: SVV BAC is as pathogenic and immunogenic as WT SVV in vivo. Thus, the SVV BAC genetic system
combined with the rhesus macaque animal model can further our understanding of viral ORFs important for VZV
pathogenesis and the development of second-generation vaccines.
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Varicella zoster virus (VZV) is a neurotropic alphaher-
pesvirus and the etiological agent of varicella (chicken-
pox) and herpes zoster (shingles). VZV establishes
latency within the sensory ganglia, and reactivation from
latency can cause significant morbidity and occasionally
mortality in older and immunocompromised individuals.
Currently the FDA vaccine Zostavax® reduces the inci-
dence of shingles by 51% and the burden of disease by
approximately 61% [1,2]. Thus, a significant portion
of vaccine recipients still remains susceptible to VZV* Correspondence: messaoud@ucr.edu
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stated.reactivation. To improve vaccine efficacy, we need to de-
termine the function of the viral open reading frames
(ORFs) that contribute to VZV pathogenesis and those
that are important for the host immune response.
Simian varicella virus (SVV) is a homolog of VZV that
causes varicella-like disease and establishes latency in
sensory ganglia of rhesus macaques [3-5]. SVV shares
significant DNA homology and genome colinearity with
VZV [6-9]. VZV and SVV have the smallest genomes of
the herpesvirus family. VZV encodes at least 70 unique
ORFs and SVV encodes 69 distinct ORFs [8,10]. Despite
the smaller genome size and homology to herpes
simplex virus (HSV), a number of VZV/SVV genes re-
main functionally uncharacterized. Studies characteriz-
ing viral gene function utilizing in vitro tissue culture
models do not always model the complex host-pathogentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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construction of an infectious SVV bacterial artificial
chromosome (BAC), the production of mutations and
deletions in specific SVV ORFs will allow the investiga-
tion of gene function during in vivo infection [11]. Previ-
ously, SVV BAC was shown to generate infectious virus
with molecular properties and in vitro replication kinet-
ics comparable to wild-type (WT) SVV [11]. SVV BAC
was also used to generate an ORF10 deletion virus,
which demonstrated that SVV ORF10 is nonessential for
replication in vitro [11]. In the current study we further
investigate SVV BAC in vivo by monitoring replication
kinetics, immune response and establishment of latency
in rhesus macaques and show that SVV BAC is as
pathogenic as WT SVV.
Results
Whole-genome analysis of SVV BAC
The BAC derived SVV viral genome was comprehen-
sively analyzed by comparative genomic hybridization
(CGH) and directly compared to wild-type (WT) SVV.
Using this technique, any differences in genomic se-
quence between SVV BAC and WT SVV results in
variations in hybridization intensities to corresponding
segments represented on the array, giving an altered
hybridization ratio between SVV BAC and WT SVV
(Figure 1A). CGH analysis revealed that two areas
displayed variations when compared to WT SVV, indi-
cating differences in nucleotide sequence at these
locations. These regions were amplified via PCR and
directly sequenced resulting in the identification of twoFigure 1 Comparative genomic hybridization and sequence analysis c
SVV genome highlighting the SVV ORFs (arrows) that contain sequence ch
indicated by the hybridization ratio between SVV BAC and WT SVV and sig
sequence variations were amplified by PCR and directly sequenced. Sequen
resulting in a missense mutation, C) within ORF 62/71 a transition from T t
number refers to the genomic position). Nucleotide substitution (bold italicnucleotide substitutions that produced 1 missense muta-
tion and 1 silent mutation within the coding region of
the SVV BAC genome. Specifically, we identified a point
mutation at nucleotide 41990 from G to A within
ORF22, producing an amino acid change from valine to
isoleucine (Figure 1B) and a transition of nucleotide
106546 from T to C producing a silent mutation within
ORF62/71 (Figure 1C). The nucleotide change in
ORF62/71 was also previously shown in the sequencing
of an ORF61 deletion virus that was generated from the
same parental SVV cosmid system [11-13]. SVV ORF22
is a putative tegument protein based on the function of
herpes simplex virus type-1 (HSV-1) UL36 homolog.
The missense mutation in ORF22 did not render SVV
BAC derived virus noninfectious or hamper replication
kinetics and plaque size in vitro [11].
Disease severity and viral load
Rhesus macaques (RMs) were infected with SVV BAC
or WT SVV at 4×105 PFU intrabronchially (n=4 per
group, sex and age matched). We investigated the patho-
genesis of BAC derived SVV in vivo by measuring dis-
ease progression, viral replication, immune response,
and the establishment of latency compared to WT SVV.
We collected bronchoalveolar lavage (BAL) cells and
blood (peripheral blood mononuclear cells, PBMC) at
various days post-infection (dpi) and sensory ganglia
were collected at necropsy (84–86 dpi). All infected
RMs displayed hallmarks of SVV infection including the
development of rash, which lasted between 7 and 10
days. A representative RM infected with SVV BAC at 7omparing SVV BAC to WT SVV. A) Schematic representation of the
anges. Sequence variation results in different hybridization intensities
nal potential nucleotide changes. B and C) The regions containing
cing identified: B) within ORF 22 a transition occurs from G to A
o C results in a silent mutation (note the nucleotide and position
s).
Meyer et al. Virology Journal 2013, 10:278 Page 3 of 12
http://www.virologyj.com/content/10/1/278dpi is shown in Figure 2A and a representative RM
infected with WT SVV at 7 dpi is shown in Figure 2B. A
lesion area was biopsied at 10 dpi and viral loads were
measured by quantitative real-time PCR (Figure 2C). By
10 dpi, we were able to detect viral DNA in all RMs ex-
cept RMs 28553 and 28621 infected with WT SVV. SVV
viral loads were also measured by quantitative real-time
PCR in BAL cells and whole blood samples. BAL cell
viral loads peaked at 3 dpi in both SVV BAC and WT
SVV infected RMs then decreased to levels near or
below our limit of detection by 63 dpi (Figure 2C). SVV
viral loads in whole blood are significantly lower than in
BAL cells, though we were able to detect SVV DNA in
whole blood between 3 and 14 dpi in RMs infected with
SVV BAC or WT SVV and then viral loads decreased to
levels near or below our limit of detection (Figure 2D).
Therefore, the ability of SVV BAC to replicate in vivo
was comparable to WT SVV.
Cytokine and chemokine levels in BAL supernatant and
plasma
We measured the concentrations of multiple chemoki-
nes (Figure 3A), cytokines (Figure 3B), and growth fac-
tors (Figure 3C) in BAL fluid and plasma (data not































Figure 2 Varicella and viral load in SVV BAC and WT SVV infected RM
BAC infected RMs. (A) SVV BAC infected RM on the trunk region and (B) W
C) skin biopsy at 10 dpi measured by quantitative PCR using primers and p
DNA. SVV DNA viral load in D) BAL and E) whole blood was measured by
SVV BAC infected RMs (open circle) and WT SVV infected RMs (closed circlewith either SVV BAC or WT SVV induced production
of several key chemokines, including MCP-1 (recruits
monocytes, memory T cells, DCs [14]), MDC (recruits
monocytes, monocyte-derived DCs, and NK cells [15]),
MIF (inflammatory and atherogenic leukocyte recruit-
ment [16]), MIG (recruits T cells [17]), MIP-1α (recruits
and activates polymorphonuclear leukocytes [18]), MIP-
1β (recruits NK cells and monocytes [18]), I-TAC (re-
cruits T cells [19]), and eotaxin (recruits eosinophils
[20]) (Figure 3). Concentrations of these chemokines
peaked at 7 dpi and returned to baseline by 14 dpi.
Concentrations of pro-inflammatory cytokines IFNγ
(involved in anti-viral activities and differentiation of T
helper 1 (Th1) subsets [21]), TNFα (systemic inflamma-
tion [22]), IL-6 (pro- and anti-inflammatory responses
[23]), IL-2 (T cell proliferation and homeostasis [24])
and IL-15 (proliferation of T cells and NK cells [25])
peaked at 7 dpi. The concentrations of IL-1 receptor an-
tagonist (RA), which prevents IL-1 from signaling
through the IL-1R [26] and IL-10 (pleiotropic activities
in inflammation and immune regulation [27]) peaked at
7 dpi. G-CSF, a pleiotropic cytokine, produced by endo-
thelium, macrophages and other immune cells, which
stimulates the survival, proliferation, differentiation, and
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s. A and B) Representative examples of varicella in WT SVV and SVV
T SVV infected RM on the axillary region at 7dpi. SVV DNA viral load in
robe specific for SVV ORF21. Average copy number per microgram of
quantitative PCR using primers and probe specific for SVV ORF21 from
). Dashed line indicates limit of detection.
MCP-1

























































































































































Figure 3 Chemokine and cytokine response in BAL fluid. Levels of (A) chemokines, (B) cytokines and (C) growth factors were determined
using multiplex technology in BAL supernatants. Concentrations of IFNα were determined by IFNα ELISA. Average pg/mL ± SEM. SVV BAC
(white bar) and WT SVV (black bar).
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into CD4 Th1 cells [29], peaked at 10 dpi. Lastly, the
concentration of IFNα, a type I interferon that is import-
ant in anti-viral immunity, peaked at 3 dpi.
Growth factors EGF (stimulates cell growth, prolifera-
tion and differentiation [30]), and FGF-basic (multifunc-
tional protein involved in angiogenesis and wound healing[31]) concentrations in BAL fluid peaked at 7 dpi. While
levels of growth factors HGF (regulates cell growth, cell
motility, and morphogenesis, and acts primarily upon
epithelial and endothelial cells [32]) and VEGF (stimulates
vasculogenesis and angiogenesis [33]) peaked at 10 dpi.
Concentrations of IL-1β, IL-4, IL-5, IL-8, IL-17, GM-
CSF and RANTES (CCL5) and in BAL fluid were below
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tect any significant differences in concentrations of
chemokines, cytokines or growth factors between RMs
infected with SVV BAC or WT SVV.
We also measured the concentration of the above
chemokines, cytokines, and growth factors in plasma
(data not shown). However, we were only able to detect
changes in the levels of IFNγ, which peaked at 7 dpi and
returned to baseline by 10 dpi and no significant differ-
ences were detected between cohorts.
B cell and antibody response to SVV BAC
We compared the magnitude and kinetics of the B
cell response as well as the generation of SVV-
specific IgG antibody titers post-infection in RMs
infected with SVV BAC or WT SVV. The expansion
of B cells is measured based on expression of Ki67, a









































































Figure 4 B cell proliferation and IgG production. The frequency of prol
flow cytometry based on the expression of Ki67 in (A) BAL and (B) PBMC.
standard ELISA. SVV BAC (open circle) and WT SVV (closed circle). Averageflow cytometry. SVV infection induces the prolifera-
tion of B cells indicated by an increase in the
frequency of Ki67 positive cells on days 7 to 14 com-
pared to day 0 in marginal zone (MZ)-like (CD27+
IgD+) and memory (CD27+IgD−) B cells, in BAL cells
(Figure 4A) and PBMC (Figure 4B). In BAL cells and
PBMC we measured similar proliferation of both sub-
sets of B cells and no statistical differences in RMs
infected with either SVV BAC or WT SVV except for
at 10 dpi in BAL cells of WT SVV infected RMs we
detected higher proliferation of MZ-like B cells
(p<0.05) compared to SVV BAC. We also measured
SVV-specific IgG (Figure 4C) antibody endpoint titers
in plasma using standard ELISA. The kinetics of IgG
production were comparable during SVV BAC and
WT SVV infection of RMs, the titers peaked around
day 14 post-infection and remained stable until
necropsy.0 3 7 10 14 17 21 28 35 49 63 84
0 3 7 10 14 17 21 28 35 49 63 84
CMBP-Byromem
memory B - BAL
SVV BAC
WT SVV
iferating in MZ-like and memory B cell subsets was measured using
SVV-specific (C) IgG antibody endpoint titers were measured by
± SEM *p<0.05.
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Naïve T cells following antigen encounter become acti-
vated, proliferate, and differentiate into central memory
(CM, CD28+CD95+) and effector memory (EM, CD28−
CD95+) T cells. We compared the kinetics and magni-
tude of the T cell response by measuring the frequency
of Ki67 positive CM and EM T cells subsets in BAL cells
(Figure 5A) and PBMC (Figure 5B) in SVV BAC or WT
SVV infected RMs. SVV BAC and WT SVV infection in-
duced strong T cell proliferation in BAL cells as shown
by an increase in Ki67 positive T cells from days 7 to 17
post-infection. Within PBMC, T cell proliferation was









































































Figure 5 T cell proliferation. The frequency of proliferating CD4 and CD8
Ki67 in central memory (CM) and effector memory (EM) subsets in (A) BAL
(closed circle).but the magnitude was significantly reduced compared
to the proliferation observed in BAL cells. Similarly
though, the magnitude and kinetics was comparable in
RMs infected with SVV BAC and WT SVV.
Additionally, we determined the frequency of SVV-
specific T cells within CD4 and CD8 T cell populations
by measuring the combined number of IFNγ-, TNFα-
and, IFNγ/TNFα-producing cells following stimulation
with either SVV lysate or a SVV overlapping peptide
pool covering ORFs 4, 31, 61 and 63 using intracellular
cytokine staining (ICS). We stimulated both BAL cells
(Figure 6A-D) and PBMC (Figure 6E,F) isolated from
infected RMs at different dpi. Within BAL cells of SVVME4DC
ME8DC
3 7 10 14 17 21 28 35 49 63 84
3 7 10 14 17 21 28 35 49 63 84
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T cells was measured by flow cytometry based on the expression of
and (B) PBMC, average ± SEM. SVV BAC (open circle) and WT SVV
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Figure 6 The frequency of responding SVV-specific T cells. The frequency of SVV-specific T cells in (A-D) BAL and (E and F) PBMC producing
IFNγ, TNFα and IFNγ/TNFα was measured by intracellular cytokine staining following stimulation with either (A, B, E and F) SVV lysate or (C and
D) overlapping peptide pool (SVV ORFs 4, 31, 61 and 63), average ± SEM. SVV BAC (white bar) and WT SVV (black bar).
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CD8 T cells were detected 7 dpi, their frequency peaked
between 14 and 21 dpi and declined to a memory set
point. There were no statistically significant differences
between animals infected with SVV BAC or WT SVV,
and both cohorts did not produce a measurable CD4 orTable 1 SVV viral load in sensory ganglia









aaverage copy number per ug of DNA.
DRG-C, cervical dorsal root ganglia; DRG-T, thoracic dorsal root ganglia; DRG-L/S, lumCD8 response in PBMCs following stimulation with
overlapping viral peptide pools (data not shown).
SVV viral load in sensory ganglia
SVV DNA viral loads in sensory ganglia were measured









bar/sacral dorsal root ganglia; ND, not detected.
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tion of the ganglia and are therefore not representative
of the entire organ. Four of the RMs went on to further
studies therefore Table 1 shows the latent viral loads for
two animals from each cohort. We detected SVV DNA
within at least one sensory ganglia of each RM infected
with SVV BAC and WT SVV indicating that the SVV
BAC, like WT SVV is able to traffic to the sensory gan-
glia, the site of SVV latency.
Discussion
Cloning viral genomes as bacterial artificial chromo-
somes (BAC) is an efficient tool to manipulate the viral
genome facilitating the study of viral genes in vitro and
in vivo. BACs were constructed for the VZV parental
Oka virus and the vaccine Oka virus [35-38]. All VZV
ORFs have been deleted using BACs or cosmids and
tested in cell culture providing valuable information on
which VZV genes are essential for viral replication
in vitro (reviewed in [39,40]). Subsequent in vivo analysis
of VZV mutant viruses using the SCID-hu mouse model
showed that VZV ORFs 1, 2, and 3 are dispensable for
viral replication [38], whereas VZV ORF23, which was
dispensable for replication in culture, was found to be
required for replication in human skin xenografts [41].
Similarly, VZV deleted for ORF7 replicated in MeWo
cells but in vivo ORF7 was shown to be important for
neuroinvasion [40,42]. Lastly, mutating the furin recog-
nition site of VZV ORF31 (gB), an essential viral protein,
did not affect VZV replication in vitro but attenuated
viral replication in vivo [43]. Studying VZV mutant vi-
ruses in the SCID-hu mouse model has provided valu-
able insight into VZV biology, further evaluation of the
role of different VZV ORFs in pathogenesis and the im-
mune response in vivo is hampered by the fact that VZV
is an obligate human pathogen. SVV is a simian homo-
log of VZV that causes varicella and zoster in nonhuman
primates [4-6].
Recently, the SVV genome was cloned as a BAC and
SVV virus generated using the SVV BAC genetic system
was found to be similar to WT SVV in vitro [11]. Muta-
genesis of SVV ORF10 showed that SVV ORF10 is non-
essential for replication in vitro [11]. Additionally,
generation of a SVV ORF 63/70 mutant demonstrated
impaired growth in Vero cells [44]. In the present study
we further the analysis of SVV BAC by infecting rhesus
macaques and investigating the pathogenesis of SVV
BAC compared to WT SVV in vivo. The combination of
the rhesus macaque animal model and the SVV BAC
will provide a robust tool to examine viral ORFs import-
ant for pathogenesis and help to target VZV ORFs that
will improve vaccine efficacy.
To compare the genome of the SVV BAC to WT SVV
we utilized comparative genomic hybridization. CGHanalysis was employed as a cost-effective and accurate
strategy to analyze genomic DNA from multiple viruses.
This technique is sensitive enough to detect single base
changes in addition to insertions, deletion or rearrange-
ments in the genome [45-47]. We sequenced two sites
in the SVV BAC genome that displayed variations in
hybridization when compared to WT SVV. In ORF22 a
point mutation at nucleotide 41990 was found produ-
cing an amino acid change from valine to isoleucine.
SVV and VZV ORF22 are putative tegument proteins
based on homology to HSV-1 UL36 [48]. UL36 is a
HSV-1 late gene and the HSV-1 virion contains 100–150
copies of UL36 [49,50]. UL36 is essential to HSV-1 repli-
cation and the phenotype of a null mutant virus showed
accumulation of capsids containing cytosolic DNA that
did not mature into enveloped virions [51-53]. Though,
the evidence suggests that the amino acid change in
SVV BAC does not constitute a significant change in the
protein. In vitro SVV BAC displays similar plaque size
and replication kinetics in Vero cell monolayers as com-
pared to WT SVV [11]. Our data in vivo shows that
SVV BAC displays similar replication kinetics, immune
response and establishment of latency compared to WT
SVV. Potentially the position of the amino acid change
or that the change is a nonpolar side chain to a nonpolar
side change allows for WT behavior.
The replication kinetics of SVV BAC in the bronchoal-
veolar lavage cells (the site of virus inoculation) and in
the peripheral blood was statistically similar to WT
SVV. Related, the spread of varicella rash was also simi-
lar between cohorts and lasted between 7 and 10 days
post-infection. In Figure 2A and B we show pictures of
two RMs infected with SVV BAC or WT SVV, which
showed representative rash and also illustrates the vari-
ation in rash spread we see in our animals. In two ani-
mals infected with WT SVV, we did not detect viral
DNA in the skin lesions but due to the nature of the
skin punch biopsies as well as the timing of the rash,
which varies between animals usually between 7 to 10
days post-infection, we may not have obtained a lesion
spot with detectable viral DNA.
We also followed the immune response to SVV BAC
during acute infection and found SVV BAC to elicit a
parallel immune response in vivo. We analyzed the pro-
liferation kinetics of antigen experienced B cells, the
production of SVV-specific IgG antibodies as well as the
proliferation kinetics of memory T cells and the IFNγ/
TNFα response of SVV-specific CD4 and CD8 T cells,
and each parameter was analogous. We did measure a
statistical difference in MZ-like B cells at 10 dpi in the
BAL where RMs infected with WT SVV displayed a
higher peak percentage of Ki67 positive cells. However,
this difference did not translate to a higher antibody titer
in the WT SVV infected RMs. This difference could be
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ture of rhesus macaques.
Infection with SVV BAC also resulted in a comparable
upregulation of chemokines, cytokines, and growth fac-
tors during the early stages of acute infection in the
lungs compared to RMs infected with WT SVV. Peak
levels of IFNα, an important antiviral cytokine, occurred
at 3 dpi, which corresponds to peak viral loads in the
lungs also at 3 dpi. Type I interferons are early immune
effectors and are important cytokines during initial in-
fection to limit viral replication and spread, including
herpesviruses [54-56]. The concentrations of several T
cell-recruiting chemokines (MCP-1, MIG, I-TAC)
peaked 7 days prior to the observed peak in proliferating
T cells in BAL samples. We also detected increased con-
centrations of TNFα (3 dpi) and IFNγ (7 dpi), which is
indicative of Th1 immune responses and correlates with
an increase in CD4 CM in BAL samples. Peak concen-
trations of IL-2 were detected 7 days prior (7 dpi) to the
peak proliferation of CD4 and CD8 T cells (14 dpi).
Levels of IL-12, which play a role in enhancing cytotoxic
function of CD8 T cells, peaked 4 days before peak pro-
liferation of CD8 T cells in BAL samples. Interestingly,
we also detected an increase in growth factors in the
BAL fluid, which peaked from 7 to 10 days post-
infection. Many of these growth factors are involved in
wound healing and might represent a response to tissue
injury induced by SVV replication within the lungs (site
of inoculation).
Lastly we found that both SVV BAC and WT SVV
established latency within the sensory ganglia. Viral
DNA was detected in at least one ganglion from each
RM measured by quantitative PCR. In summary, SVV
BAC is as pathogenic in vivo as WT SVV. Future studies
will utilize the SVV BAC genetic system to generate
knockout viruses to help characterize the role of SVV
genes in acute infection, the establishment and mainten-
ance of latency, and reactivation in vivo, a critical step in
the understanding of viral factors that impact VZV
pathogenesis and the immune response to VZV.
Materials and methods
Cells and viruses
Bacterial artificial chromosome (BAC)-derived SVV was
generated from self-excisable pSVV-BAC resulting in
complete excision of plasmid sequences from the virus
genome [11]. Wild-type (WT) simian varicella virus
(SVV, Cercopithecine herpesvirus 9) and SVV BAC
were propagated as previously described, briefly Vero
cells maintained in Eagle’s minimal essential medium
(EMEM) supplemented with 5% newborn bovine serum,
penicillin and streptomycin, WT SVV and SVV BAC
infected Veros were harvested by scraping and frozen in
Vero media supplemented with 10% dimethyl sulfoxide(DMSO) [11]. Virus stocks were titered by plaque assay
on primary rhesus fibroblasts maintained in Dulbecco’s
modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum and penicillin, streptomycin and
L-glutamine. WT SVV cell lysate was obtained by scrap-
ing infected primary rhesus fibroblasts at the height of
CPE followed by centrifugation and sonication using
7 pulses of 70–80 Watts (Sonicator 3000, Misonix Inc.,
Farmingdale NY) and frozen at −80°C.Animals and sample collection
All rhesus macaques were housed at the Oregon Na-
tional Primate Research Center and were handled in ac-
cordance with good animal practices as defined by the
Office of Laboratory Animal Welfare. Animal work was
approved by the Oregon National Primate Research
Center Institutional Animal Care and Use Committee.
Rhesus macaques (RM, Macaca mulatta) were SVV
seronegative prior to infection measured by ELISA. RMs
(n=4 per group) were infected intrabronchially with
4×105 PFU WT SVV or SVV BAC infected Veros. Per-
ipheral blood mononuclear cells (PBMC) and bronchoal-
veolar lavage (BAL) cells were collected from rhesus
macaques as previously described [5]. Animals were eu-
thanized at 84 to 86 days post-infection. Sensory ganglia:
trigeminal ganglia (TG), cervical, thoracic and lumbar-
sacral dorsal root ganglia (DRG-C, DRG-T, and DRG-
L/S respectively) were divided, flash frozen and stored
at −80°C until analysis.Comparative genome analysis of SVV BAC and SVV WT
DNA
A microarray hybridization-based method was used to
compare SVVΔORF61 genomic DNA (test) to WT SVV
(reference) DNA provided by NimbleGen Systems, Inc.
(CGS 385K Mutation Mapping array Phase 1, Madison
WI). Design of the microarray used published sequence
data for the Delta herpesvirus strain of SVV (NC_00
2686, [8]). The oligonucleotides were 29–39 bp in length
and tiled throughout the genome every 7–8 bases on
both forward and reverse strands. Viral DNA was iso-
lated from nucleocapsids purified from SVV-infected
Vero cells as previously described [7]. Hybridization data
was analyzed using SignalMap software (NimbleGen
Systems, Inc., Madison WI). The identified mismatches
were directly sequenced from PCR products obtained
from amplifying the surrounding sequence. The primers
employed for Figure 1 include: (B) primer 1, 5′-CCATA
TGTACCAACGGGAACA-3′ and primer 2, 5′-AAGCA
TGCATTTTCGATTGGA-3′; (C) primer 1, 5′-GCCTG
GAGCCCAGATATTCGA-3′ and primer 2, 5′-ACGGT
GTGCGTGGATGCATCA-3′.
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DNA was extracted from heparinized whole blood (WB),
BAL cells, and portions of frozen ganglia using Archive
Pure DNA Cell/Tissue Kit (5 PRIME, Gaithersburg MD)
according to the manufacturer’s protocol. SVV DNA
viral loads in WB, BAL cells and sensory ganglia were
measured by qPCR using Maxima Probe/ROX qPCR
Master Mix (2X) (Fermentas, Glen Burnie MD) and
primers/Taqman probe specific for SVV ORF21. Follow-
ing an initial 10 minute 95°C step, 40 cycles of 15 sec at
95°C and 1 minute at 60°C were completed using
StepOnePlus (Life Technologies, Carlsbad CA). SVV
BAC DNA was used as quantification standards [11].
Cytokine analysis
Plasma and BAL supernatant samples (stored at −80°C)
were thawed and analyzed using Cytokine Monkey Mag-
netic 28-plex panel as per the manufacturer’s instruc-
tions (Life Technologies). IFNα levels were measured
using Cynomolgus/Rhesus IFNα Serum ELISA Kit ac-
cording to the manufacturer’s instructions (PBL Inter-
feron Source, Piscataway NJ). Samples were run in
duplicate. Values below the limit of detection were des-
ignated as ND, or not detected.
Enzyme-linked immunosorbent assay (ELISA)
ELISA plates were coated with SVV lysate overnight at
4°C, blocked with 5% milk in wash buffer (0.05% Tween
in PBS) for 1 h at room-temperature (RT), washed three
times with wash buffer, and incubated with heat-
inactivated (55°C, 30 min) plasma samples in 3-fold dilu-
tions in duplicate for 1 h. After washing three times with
wash buffer, horseradish peroxidase (HRP)-conjugated
anti-rhesus IgG (Nordic Immunology, Netherlands) was
added for 1 h, followed by addition of chromagen o-
phenylenediamine•2HCl (OPD) (Sigma, St Louis MO)
substrate for 20 minutes to allow detection and quantita-
tion of bound antibody molecules. The reaction was
stopped with the addition of 1 M HCl. The optical dens-
ity was measured at 490 nm using an ELISA plate reader
(SpectraMax 190, Molecular Devices, Sunnyvale CA).
Endpoint IgG titers were calculated using log-log trans-
formation of the linear portion of the curve with 0.1 op-
tical density (OD) units as the cut-off. Titers were
standardized using a positive control sample included
with each assay.
Measurement of T cell and B cell frequency and
proliferation
BAL cells and PBMC were surface stained with anti-
bodies against 1) CD4 (eBioscience, San Diego CA),
CD8β (Beckman Coulter), CD28, and CD95 (BioLegend,
San Diego CA) to delineate the naive (CD28+CD95−),
central memory (CD28+CD95+), and effector memory(CD28−CD95+) T cell subsets; 2) CD20 (Beckman
Coulter, Brea CA), IgD (Southern Biotech, Birmingham
AL), and CD27 (BioLegend) to delineate naïve (CD20+
IgD+CD27−), marginal zone-like (MZ-like) (CD20+IgD+
CD27+), and memory (CD20+IgD−CD27+) B cell subsets.
Cells were fixed and permeabilized according to manufac-
turer recommendations (BioLegend) before the addition
of Ki67-specific antibody (BD Biosciences, San Jose, CA).
The samples were analyzed using the LSRII instrument
(Beckton, Dickinson and Company, San Jose CA) and
FlowJo software (TreeStar, Ashland OR).
Intracellular cytokine staining
BAL cells and PBMC were stimulated with SVV lysate
(1 μg) or SVV overlapping peptide pool containing open
reading frames (ORFs) 4, 31, 61 and 63 for 1 h followed by
addition of Brefeldin A (Sigma, St Louis MO) to block cyto-
kine export for 14 h. After stimulation cells were surface
stained with antibodies against CD4, and CD8β, as described
above. Samples were fixed, permeabilized (BioLegend) and
dual-stained using antibodies against IFNγ (eBioscience) and
TNFα (eBioscience). Samples were analyzed using the LSRII
instrument and FlowJo software.
Statistical analysis
Statistical analysis and graphing was conducted with
GraphPad Prism software (GraphPad Software Inc.,
La Jolla CA). Significance values for Figures 2, 3, 4, 5,
and 6 utilized repeated measures of ANOVA with the
Bonferroni post-test to explore differences between
groups (SVV BAC and WT SVV) at each time-point.
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